This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Nutritional and Metabolic Disorders, Other  • Dermatology  • Dermatologic Disorders  • Psoriasis  • Drug Therapy  • Adverse Effects  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Jia-Jen Wu, MD; Tsen-Fang Tsai, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Tumor necrosis factor (TNF) inhibitors are increasingly used in psoriasis treatment. We describe a patient with psoriasis and diabetes mellitus (DM) who developed recurrent hyperglycemia during adalimumab treatment.

Report of a Case

The patient presented in 1999 at age 31 years with a 4-year history of psoriasis and psoriatic spondylarthritis. Different systemic treatments, including UV-B, efalizumab, cyclosporine, and acitretin were tried but were discontinued owing either to toxic effects or lack of efficacy. Photochemotherapy proved most effective, but the patient discontinued therapy owing to its inconvenience.

The patient had type 2 DM since 2003, and the disease was well controlled with glimepiride (postprandial serum glucose level, 120-130 mg/dL). (To convert serum glucose to millimoles per liter, multiply by 0.0555.) In 2006, the patient received methotrexate and etanercept, 50 mg once or twice weekly, for 6 months without adverse effects. His psoriatic arthritis improved significantly, but the cutaneous lesions . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?